

CITATION REPORT

List of articles citing

Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy

DOI: 10.1177/112067210901900415

European Journal of Ophthalmology, 2009, 19, 613-7.

Source: <https://exaly.com/paper-pdf/45336821/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
76	Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. <i>Retina</i> , 2010 , 30, 1465-71	3.6	61
75	[Central serous chorioretinopathy (CSC)]. <i>Ophthalmologe</i> , 2010 , 107, 479-92; quiz 493	1.6	9
74	Central serous chorioretinopathy: an update on pathogenesis and treatment. <i>Eye</i> , 2010 , 24, 1743-56	4.4	226
73	A Case of Central Serous Chorioretinopathy Associated With Retinal Detachment Improved by Intravitreal Bevacizumab Injection. <i>Journal of Korean Ophthalmological Society</i> , 2010 , 51, 1419	0.2	1
72	Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. <i>European Journal of Ophthalmology</i> , 2010 , 20, 955-8	1.9	24
71	Low-dose aspirin as treatment for central serous chorioretinopathy. <i>Clinical Ophthalmology</i> , 2010 , 4, 899-903	2.5	37
70	Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. 2010 , 51, 3575-82		70
69	Role of Avastin in management of central serous chorioretinopathy. <i>Saudi Journal of Ophthalmology</i> , 2010 , 24, 69-75	0.9	10
68	Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2011 , 86, 407-411	0.1	
67	[Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection]. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2011 , 86, 407-11	0.5	3
66	Finasteride for chronic central serous chorioretinopathy. <i>Retina</i> , 2011 , 31, 766-71	3.6	53
65	Alterations in "in vivo" histology of retina in bilateral chronic central serous chorioretinopathy after intravitreal bevacizumab. <i>Journal of Ocular Biology, Diseases, and Informatics</i> , 2011 , 4, 137-40		1
64	The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. <i>Graefels Archive for Clinical and Experimental Ophthalmology</i> , 2011 , 249, 969-74	3.8	40
63	Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. <i>Graefels Archive for Clinical and Experimental Ophthalmology</i> , 2011 , 249, 1159-66	3.8	15
62	Central serous retinopathy. <i>Arthritis Care and Research</i> , 2011 , 63, 1075-82	4.7	5
61	Spectral domain optical coherence tomography findings of an iatrogenic retinal diamond deposit. <i>Eye</i> , 2011 , 25, 1518-9	4.4	1
60	Neurosensory retinal detachment due to sunitinib treatment. <i>Eye</i> , 2011 , 25, 1517-8	4.4	16

59	Vascular endothelial growth factor inhibition in uveitis: a systematic review. <i>British Journal of Ophthalmology</i> , 2011 , 95, 162-5	5.5	40
58	Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy. <i>Ophthalmologica</i> , 2011 , 225, 37-40	3.7	41
57	Intravitreal bevacizumab for subfoveal choroidal neovascularization complicating active central serous chorioretinopathy. <i>Indian Journal of Ophthalmology</i> , 2011 , 59, 338-9	1.6	6
56	An Update on the Diagnosis and Management of Central Serous Chorioretinopathy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012 , 1, 296-302	3.5	4
55	Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. <i>Eye</i> , 2012 , 26, 307-14	4.4	73
54	[Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab]. <i>Ophthalmologie</i> , 2012 , 109, 1224-32	1.6	9
53	Short-term efficacy of intravitreal dopesilate in central serous chorioretinopathy. <i>European Journal of Medical Research</i> , 2012 , 17, 22	4.8	7
52	Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy. <i>Korean Journal of Ophthalmology: KJO</i> , 2012 , 26, 139-42	1.2	9
51	The Efficacy of Intravitreal Bevacizumab Injection in Patients with Acute Central Serous Chorioretinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2012 , 53, 781	0.2	3
50	Photodynamic Therapy for Chronic Central Serous Chorioretinopathy According to Degree of Choroidal Hyperfluorescence. <i>Journal of Korean Ophthalmological Society</i> , 2012 , 53, 268	0.2	1
49	Intravitreal injection of bevacizumab for chronic central serous chorioretinopathy. <i>Taiwan Journal of Ophthalmology</i> , 2013 , 3, 67-70	1.4	
48	Central Serous Chorioretinopathy. 2013 , 1291-1305		6
47	Nonrhegmatogenous Retinal Detachment. 2013 , 1622-1639		1
46	Central serous chorioretinopathy: update on pathophysiology and treatment. <i>Survey of Ophthalmology</i> , 2013 , 58, 103-26	6.1	389
45	Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. <i>Eye</i> , 2013 , 27, 1339-46	4.4	58
44	Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. <i>Eye</i> , 2013 , 27, 353-62	4.4	21
43	Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. <i>Retina</i> , 2013 , 33, 2096-102	3.6	152
42	Diagnosis and interventions for central serous chorioretinopathy: review and update. <i>Clinical and Experimental Ophthalmology</i> , 2013 , 41, 187-200	2.4	57

41	The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013 , 29, 10-3	2.6	19
40	The stress response as a target for treatment of central serous chorioretinopathy. <i>Expert Review of Ophthalmology</i> , 2013 , 8, 457-468	1.5	
39	Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. <i>Clinical Ophthalmology</i> , 2013 , 7, 939-45	2.5	40
38	Comparison of Therapeutic Effect Between Half-Energy Photodynamic Therapy and Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy for 12 Months. <i>Journal of Korean Ophthalmological Society</i> , 2013 , 54, 1526	0.2	3
37	Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab. <i>Cutaneous and Ocular Toxicology</i> , 2014 , 33, 122-6	1.8	11
36	Treatment of persistent serous retinal detachment in Vogt-Koyanagi-Harada syndrome with intravitreal bevacizumab during the systemic steroid treatment. <i>Retina</i> , 2014 , 34, 490-6	3.6	15
35	[Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy]. <i>Ophthalmologie</i> , 2014 , 111, 173-80	1.6	15
34	Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. <i>Ophthalmology</i> , 2014 , 121, 558-65	7.3	48
33	Hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy. <i>Case Reports in Ophthalmology</i> , 2014 , 5, 207-11	0.7	1
32	SUBFOVEAL CHOROIDAL THICKNESS CHANGES IN TREATED IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY AND THEIR ASSOCIATION WITH RECURRENCE. <i>Retina</i> , 2015 , 35, 1867-74	3.6	26
31	Comparison of Choroidal Hyperpermeability Change after Photodynamic Therapy and Ranibizumab for Chronic Central Serous Chorioretinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2015 , 56, 205 ^{0.2}		2
30	The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. <i>Korean Journal of Ophthalmology: KJO</i> , 2015 , 29, 160-7	1.2	9
29	Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy. <i>Clinical Ophthalmology</i> , 2015 , 9, 2257-61	2.5	2
28	Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. <i>Progress in Retinal and Eye Research</i> , 2015 , 48, 82-118	20.5	480
27	Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. <i>Graefels Archive for Clinical and Experimental Ophthalmology</i> , 2015 , 253, 2129-35	3.8	41
26	Advances in the treatment of central serous chorioretinopathy. <i>Saudi Journal of Ophthalmology</i> , 2015 , 29, 278-86	0.9	19
25	Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. <i>Eye</i> , 2015 , 29, 732-40; quiz 741	4.4	15
24	Treatment of Chronic Central Serous Chorioretinopathy with Oral Methotrexate. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2015 , 31, 468-75	2.6	8

23	Exudative retinal detachment. <i>Survey of Ophthalmology</i> , 2017 , 62, 723-769	6.1	27
22	Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. <i>International Journal of Clinical Pharmacy</i> , 2017 , 39, 514-521	2.3	19
21	Retinal Pigment Epithelial Detachment. 2017 ,		2
20	Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. <i>International Ophthalmology</i> , 2017 , 37, 1115-1125	2.2	32
19	Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy. <i>Journal of Current Ophthalmology</i> , 2019 , 31, 406-410	2	3
18	Increased risk of central serous chorioretinopathy following end-stage renal disease: A nationwide population-based study. <i>Medicine (United States)</i> , 2019 , 98, e14859	1.8	4
17	Central Serous Chorioretinopathy: Pathogenesis and Management. <i>Clinical Ophthalmology</i> , 2019 , 13, 2341-2352	2.5	25
16	Abnormal choroidal flow on optical coherence tomography angiography in central serous chorioretinopathy. <i>Clinical and Experimental Ophthalmology</i> , 2019 , 47, 505-512	2.4	5
15	TWELVE-MONTH EFFICACY OF INTRAVITREAL BEVACIZUMAB INJECTION FOR CHRONIC, ATYPICAL, OR RECURRENT CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2019 , 39, 134-142	3.6	14
14	An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study. <i>Acta Ophthalmologica</i> , 2019 , 98, e549	3.7	5
13	Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy. <i>PLoS ONE</i> , 2020 , 15, e0238725	3.7	1
12	Clinical Effects of Non-damaging Retinal Laser Therapy in Chronic Central Serous Chorioretinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2021 , 62, 222-229	0.2	
11	Comparison of Intravitreal Bevacizumab and Aflibercept Injections for Central Serous Chorioretinopathy. <i>Journal of Korean Ophthalmological Society</i> , 2021 , 62, 957-962	0.2	
10	Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography. <i>PLoS ONE</i> , 2021 , 16, e0245342	3.7	0
9	Treatment of Retinal Detachment. 2021 , 211-238		
8	Clinical research of fenofibrate and spironolactone for acute central serous chorioretinopathy. <i>International Journal of Ophthalmology</i> , 2016 , 9, 1444-1450	1.4	2
7	The effect of selective retina therapy for bevacizumab-resistant chronic central serous chorioretinopathy. <i>Ophthalmologica</i> , 2021 ,	3.7	0
6	What is new in central serous chorioretinopathy?. <i>World Journal of Ophthalmology</i> , 2014 , 4, 113	0	

- 5 Updates in Central Serous Chorioretinopathy. *Highlights of Ophthalmology*, **2016**, 44, 9-20 0
- 4 Retinal Pigment Epithelial Detachment in Central Serous Chorioretinopathy. **2017**, 135-152
- 3 Ranibizumab in the Treatment of Chronic Central Serous Chorio Retinopathy. *Advances in Ophthalmology & Visual System*, **2017**, 6, 2
- 2 Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). *Transactions of the American Ophthalmological Society*, **2015**, 113, T8 13
- 1 Factors Predicting Response to Selective Retina Therapy in Patients with Chronic Central Serous Chorioretinopathy.. *Journal of Clinical Medicine*, **2022**, 11, 5-1